Why the study?
Severe aortic stenosis carries a poor prognosis without valve replacement, and some patients are at high surgical risk, prompting the ongoing development and adoption of transcatheter aortic valve implantation.
TAVI has revolutionized the management of aortic stenosis and is becoming a safer, widely accepted alternative to surgery.
Answers are grounded in this paper and cite their sources.
May guide high-risk aortic stenosis referrals; leaves open randomized durability data versus surgery.
Aortic stenosis is a valvular heart disease commonly found in developed and developing countries. The frequency of aortic valve sclerosis is about 25% in people over 65 years of age. In contrast to developing countries, infectious diseases, such as endocarditis or rheumatic fever, contribute greatly to aortic stenosis. Severe aortic stenosis without valve replacement has a poor prognosis and some patients are at high risk for surgery. Transcatheter aortic valve implantation (TAVI) is emerging as an alternative in patients with aortic stenosis who cannot or are at high risk for surgery. TAVI has revolutionized the management of aortic stenosis. This procedure continues to improve yearly and exceeds surgical aortic valve replacement in 2019. Initially, TAVI generated skepticism and criticism, but with many clinical trials and evidence-based investigations, TAVI is now widely accepted. Until now, the development of TAVI continues, starting with better technology, approaches, and new implantation strategies; TAVI is becoming safer for patients. This literature review will discuss more deeply about TAVI and its development.
No takes yet. Share an insight, caveat, or question.
Rampengan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: